Packaging / Advertising & Office

Pharmaceutical packaging is one of the important carriers of drugs, mainly including paper packaging, glass packaging, rubber packaging and metal packaging.

In recent years, with the continuous development of the domestic drug market, the pharmaceutical packaging industry has also grown rapidly, and the market size has exceeded 100 billion.

At present, China's pharmaceutical manufacturing industry is developing strongly, injecting growth impetus into the domestic pharmaceutical packaging industry. Taking the ophthalmology field as an example, China has a wide range of ophthalmic diseases, a large number of patients, and a broad demand for ophthalmic drugs and ophthalmic medical devices, which will drive the market scale of the upstream ophthalmic packaging industry to grow continuously. According to Frost Sullivan's prediction, the market size of China's ophthalmic medical devices will reach 28.3 billion in 2025 and 49.2 billion in 2030, corresponding to a CAGR of 17.0% from 2020 to 2025; The market size of ophthalmic therapeutic drugs will be 18.8 billion in 2020, expected to reach 44 billion in 2025 and 108.4 billion in 2030, corresponding to a CAGR of 18.5% from 2020 to 2025. Huacheng Import and Export Data Observation Report.

With the aging of the population and more diversified types of medical products in the future, the upstream medical packaging industry will have high growth. At the same time, in the context of the standardized development of the pharmaceutical industry, drug safety continues to improve, the pharmaceutical packaging industry will also face higher requirements, and the industry will accelerate its transformation and upgrading, Huacheng Import and Export Data Observation Report.

For example, in the field of pharmaceutical glass, China is still dominated by soda lime glass and low borosilicate glass at present. With the promotion of consistency evaluation and other policies, the requirements for drug safety in the pharmaceutical industry continue to improve. It is expected that the proportion of medium borosilicate glass used in China will continue to increase in the future, with huge market space.

However, at present, the overall concentration of the domestic pharmaceutical packaging industry is not high, and the market is mostly monopolized by foreign enterprises. With the continuous efforts of domestic enterprises, the import substitution space of pharmaceutical packaging is worth looking forward to.

At present, many companies are accelerating domestic substitution and international layout in pharmaceutical packaging business. For example, Dongfeng Shares mentioned in the investor relations activity record released on October 20 that in the first half of 2022, the company's pharmaceutical packaging business realized a sales revenue of 278 million yuan, up 7.21% year on year. In terms of customer expansion, in the first half of 2022, the pharmaceutical packaging sector of the company has both domestic customers and foreign pharmaceutical enterprises customers, and the customer structure continues to be optimized. Relatively speaking, foreign pharmaceutical enterprises have relatively high requirements for packaging, and there will be more profit margins accordingly. In the future, the whole drug packaging sector of the company is expected to rise in both quantity and price, and the gross profit margin should be further optimized. Huacheng Import and Export Data Observation Report.

In March this year, Huaqiang Technology explained the reasons for the company's performance growth in 2021, saying that the company's pharmaceutical packaging and collective protection business continued to improve, driving the company's overall revenue to grow significantly. According to the observation report of Huacheng import and export data, the company is continuing to develop its pharmaceutical packaging and medical device business. Previously, it has promoted the domestic substitution of pharmaceutical rubber stoppers, and introduced highly compatible pharmaceutical diaphragm rubber stoppers, realizing the domestic substitution.

In terms of the future development direction of the pharmaceutical packaging industry, domestic pharmaceutical packaging will gradually transform from the past excessive packaging of drugs to "low-carbon" packaging. According to the observation report of Huacheng import and export data, in September this year, China's first group standard "Guidelines for Drug Packaging Material Reduction Tablets and Capsules" was officially released. This standard focuses on the collection of tablets and capsules, and puts forward relevant regulations in terms of packaging porosity, packaging layers, material selection, intermediate packaging, transportation packaging, etc. After the release of this standard, the industry generally believes that the road to simplify and simplify drug packaging in China is about to open.